Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
44.28
-0.28 (-0.63%)
At close: Apr 3, 2025, 4:00 PM
44.37
+0.09 (0.20%)
After-hours: Apr 3, 2025, 7:55 PM EDT
Exact Sciences Revenue
In the year 2024, Exact Sciences had annual revenue of $2.76B with 10.37% growth. Exact Sciences had revenue of $713.42M in the quarter ending December 31, 2024, with 10.29% growth.
Revenue (ttm)
$2.76B
Revenue Growth
+10.37%
P/S Ratio
2.96
Revenue / Employee
$394,124
Employees
7,000
Market Cap
8.23B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.76B | 259.10M | 10.37% |
Dec 31, 2023 | 2.50B | 415.49M | 19.93% |
Dec 31, 2022 | 2.08B | 317.19M | 17.95% |
Dec 31, 2021 | 1.77B | 275.70M | 18.49% |
Dec 31, 2020 | 1.49B | 615.10M | 70.19% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
EXAS News
- 2 days ago - Exact Sciences Schedules First Quarter 2025 Earnings Call - Business Wire
- 3 days ago - Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening - Business Wire
- 22 days ago - Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner - Business Wire
- 22 days ago - New Data Highlight the Positive Impact of Exact Sciences' Oncotype DX® Test on Patient Care and Healthcare Efficiency - Business Wire
- 5 weeks ago - Exact Sciences to Participate in March Investor Conferences - Business Wire
- 5 weeks ago - Exact Sciences: A Strong Q4 Reveals Signs Of A Potential Inflection Point - Seeking Alpha
- 6 weeks ago - Exact Sciences Corporation (EXAS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Exact Sciences Announces Fourth Quarter 2024 Results - Business Wire